VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q83900113  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241221010857.0
008     241221nneanz||abbn n and d
035 ‎‡a  (WKP)Q83900113‏
024 ‎‡a  0000-0002-7634-6812‏ ‎‡2  orcid‏
024 ‎‡a  55450211700‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q83900113‏
100 0 ‎‡a  Jan Nielsen‏ ‎‡9  da‏
400 0 ‎‡a  Jan Nielsen‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  J Nielsen‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's Analyzing multivariate survival data using composite likelihood and flexible parametric modeling of the hazard functions.‏
670 ‎‡a  Author's Anti-TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate-severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight‏
670 ‎‡a  Author's Can family history and cord blood IgE predict sensitization and allergic diseases up to adulthood?‏
670 ‎‡a  Author's Comparison of Time to Pregnancy in Women With and Without Inflammatory Bowel Diseases‏
670 ‎‡a  Author's Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison‏
670 ‎‡a  Author's Early pregnancy angiogenic markers and spontaneous abortion: an Odense Child Cohort study‏
670 ‎‡a  Author's Editorial: anti-TNF therapy-a double-edged sword? Authors' reply‏
670 ‎‡a  Author's Fecal Calprotectin During Pregnancy in Women With Moderate-Severe Inflammatory Bowel Disease.‏
670 ‎‡a  Author's Heritability of clubfoot: a twin study‏
670 ‎‡a  Author's In utero exposure to thiopurines/anti-TNF agents and long-term health outcomes during childhood and adolescence in Denmark‏
670 ‎‡a  Author's Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease‏
670 ‎‡a  Author's Letter: number of treatments with anti-TNF-α and reoperations in inflammatory bowel disease.‏
670 ‎‡a  Author's Paternal use of medications for inflammatory bowel disease and the risk of hospital‐diagnosed infections in the offspring: a nationwide cohort study‏
670 ‎‡a  Author's Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases.‏
670 ‎‡a  Author's Postoperative Use of Anti-TNF-α Agents in Patients with Crohn's Disease and Risk of Reoperation-A Nationwide Cohort Study.‏
670 ‎‡a  Author's Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease--a nationwide cohort study.‏
670 ‎‡a  Author's Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study.‏
670 ‎‡a  Author's Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort.‏
670 ‎‡a  Author's Reply: To PMID 25420698‏
670 ‎‡a  Author's Risk factors and between-hospital variation of caesarean section in Denmark: a cohort study.‏
670 ‎‡a  Author's S-25-hydroxyvitamin D and C3-epimers in pregnancy and infancy: An Odense Child Cohort study.‏
670 ‎‡a  Author's Sexual health in women with inflammatory bowel disease in the Danish National Birth Cohort‏
670 ‎‡a  Author's The Danish Neuro-Oncology Registry: establishment, completeness and validity.‏
670 ‎‡a  Author's The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease.‏
670 ‎‡a  Author's The incidence of ulcerative colitis (1995-2011) and Crohn's disease (1995-2012) - based on nationwide Danish registry data‏
670 ‎‡a  Author's The natural course of sensitization and allergic diseases from childhood to adulthood.‏
670 ‎‡a  Author's Vitamin D insufficiency is associated with increased risk of first-trimester miscarriage in the Odense Child Cohort.‏
670 ‎‡a  Author's Vitamin D supplementation, cord 25-hydroxyvitamin D and birth weight: Findings from the Odense Child Cohort.‏
909 ‎‡a  (orcid) 0000000276346812‏ ‎‡9  1‏
909 ‎‡a  (scopus) 55450211700‏ ‎‡9  1‏
919 ‎‡a  s25hydroxyvitamin500andc3epimersinpregnancyandinfancyanodensechildcohortstudy‏ ‎‡A  S-25-hydroxyvitamin D and C3-epimers in pregnancy and infancy: An Odense Child Cohort study.‏ ‎‡9  1‏
919 ‎‡a  sexualhealthinwomenwithinflammatoryboweldiseaseinthedanishnationalbirthcohort‏ ‎‡A  Sexual health in women with inflammatory bowel disease in the Danish National Birth Cohort‏ ‎‡9  1‏
919 ‎‡a  vitamin500supplementationcord25hydroxyvitamin500andbirthweightfindingsfromtheodensechildcohort‏ ‎‡A  Vitamin D supplementation, cord 25-hydroxyvitamin D and birth weight: Findings from the Odense Child Cohort.‏ ‎‡9  1‏
919 ‎‡a  analyzingmultivariatesurvivaldatausingcompositelikelihoodandflexibleparametricmodelingofthehazardfunctions‏ ‎‡A  Analyzing multivariate survival data using composite likelihood and flexible parametric modeling of the hazard functions.‏ ‎‡9  1‏
919 ‎‡a  antitnfαuseduringthe3trimesterofpregnancyinwomenwithmoderatesevereinflammatoryboweldiseaseandtheriskofpretermbirthandlowbirthweight‏ ‎‡A  Anti-TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate-severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight‏ ‎‡9  1‏
919 ‎‡a  canfamilyhistoryandcordbloodigepredictsensitizationandallergicdiseasesuptoadulthood‏ ‎‡A  Can family history and cord blood IgE predict sensitization and allergic diseases up to adulthood?‏ ‎‡9  1‏
919 ‎‡a  comparisonoftimetopregnancyinwomenwithandwithoutinflammatoryboweldiseases‏ ‎‡A  Comparison of Time to Pregnancy in Women With and Without Inflammatory Bowel Diseases‏ ‎‡9  1‏
919 ‎‡a  diagnosisofpreeclampsiawithsolublefmsliketyrosinekinase1placentalgrowthfactorratioaninterassaycomparison‏ ‎‡A  Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison‏ ‎‡9  1‏
919 ‎‡a  earlypregnancyangiogenicmarkersandspontaneousabortionanodensechildcohortstudy‏ ‎‡A  Early pregnancy angiogenic markers and spontaneous abortion: an Odense Child Cohort study‏ ‎‡9  1‏
919 ‎‡a  editorialantitnftherapyadoubleedgedswordauthorsreply‏ ‎‡A  Editorial: anti-TNF therapy-a double-edged sword? Authors' reply‏ ‎‡9  1‏
919 ‎‡a  fecalcalprotectinduringpregnancyinwomenwithmoderatesevereinflammatoryboweldisease‏ ‎‡A  Fecal Calprotectin During Pregnancy in Women With Moderate-Severe Inflammatory Bowel Disease.‏ ‎‡9  1‏
919 ‎‡a  vitamin500insufficiencyisassociatedwithincreasedriskof1trimestermiscarriageintheodensechildcohort‏ ‎‡A  Vitamin D insufficiency is associated with increased risk of first-trimester miscarriage in the Odense Child Cohort.‏ ‎‡9  1‏
919 ‎‡a  naturalcourseofsensitizationandallergicdiseasesfromchildhoodtoadulthood‏ ‎‡A  The natural course of sensitization and allergic diseases from childhood to adulthood.‏ ‎‡9  1‏
919 ‎‡a  incidenceofulcerativecolitis19952011andcrohnsdisease19952012basedonnationwidedanishregistrydata‏ ‎‡A  The incidence of ulcerative colitis (1995-2011) and Crohn's disease (1995-2012) - based on nationwide Danish registry data‏ ‎‡9  1‏
919 ‎‡a  effectofdiseaseactivityonbirthoutcomesinanationwidecohortofwomenwithmoderatetosevereinflammatoryboweldisease‏ ‎‡A  The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease.‏ ‎‡9  1‏
919 ‎‡a  danishneurooncologyregistryestablishmentcompletenessandvalidity‏ ‎‡A  The Danish Neuro-Oncology Registry: establishment, completeness and validity.‏ ‎‡9  1‏
919 ‎‡a  heritabilityofclubfootatwinstudy‏ ‎‡A  Heritability of clubfoot: a twin study‏ ‎‡9  1‏
919 ‎‡a  inuteroexposuretothiopurinesantitnfagentsandlongtermhealthoutcomesduringchildhoodandadolescenceindenmark‏ ‎‡A  In utero exposure to thiopurines/anti-TNF agents and long-term health outcomes during childhood and adolescence in Denmark‏ ‎‡9  1‏
919 ‎‡a  increasedriskofdevelopingcrohnsdiseaseorulcerativecolitisin17018patientswhileundertreatmentwithantitnfαagentsparticularlyetanerceptforautoimmunediseasesotherthaninflammatoryboweldisease‏ ‎‡A  Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease‏ ‎‡9  1‏
919 ‎‡a  letternumberoftreatmentswithantitnfαandreoperationsininflammatoryboweldisease‏ ‎‡A  Letter: number of treatments with anti-TNF-α and reoperations in inflammatory bowel disease.‏ ‎‡9  1‏
919 ‎‡a  paternaluseofmedicationsforinflammatoryboweldiseaseandtheriskofhospitaldiagnosedinfectionsintheoffspringanationwidecohortstudy‏ ‎‡A  Paternal use of medications for inflammatory bowel disease and the risk of hospital‐diagnosed infections in the offspring: a nationwide cohort study‏ ‎‡9  1‏
919 ‎‡a  patientswithinflammatoryboweldiseasehaveincreasedriskofautoimmuneandinflammatorydiseases‏ ‎‡A  Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases.‏ ‎‡9  1‏
919 ‎‡a  postoperativeuseofantitnfαagentsinpatientswithcrohnsdiseaseandriskofreoperationanationwidecohortstudy‏ ‎‡A  Postoperative Use of Anti-TNF-α Agents in Patients with Crohn's Disease and Risk of Reoperation-A Nationwide Cohort Study.‏ ‎‡9  1‏
919 ‎‡a  preoperativeuseofantitnfαagentsandtheriskofpostoperativecomplicationsinpatientswithcrohnsdiseaseanationwidecohortstudy‏ ‎‡A  Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease--a nationwide cohort study.‏ ‎‡9  1‏
919 ‎‡a  preoperativeuseofantitnfαagentsandtheriskofpostoperativecomplicationsinpatientswithulcerativecolitisanationwidecohortstudy‏ ‎‡A  Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study.‏ ‎‡9  1‏
919 ‎‡a  predictionofpreeclampsiawithangiogenicbiomarkersresultsfromtheprospectiveodensechildcohort‏ ‎‡A  Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort.‏ ‎‡9  1‏
919 ‎‡a  replytopmid25420698‏ ‎‡A  Reply: To PMID 25420698‏ ‎‡9  1‏
919 ‎‡a  riskfactorsandbetweenhospitalvariationofcaesareansectionindenmarkacohortstudy‏ ‎‡A  Risk factors and between-hospital variation of caesarean section in Denmark: a cohort study.‏ ‎‡9  1‏
996 ‎‡2  DBC|87097968773245
996 ‎‡2  DBC|87097968082781
996 ‎‡2  LC|n 80038040
996 ‎‡2  W2Z|7053342
996 ‎‡2  ISNI|0000000429290531
996 ‎‡2  ISNI|0000000500939787
996 ‎‡2  W2Z|1492758307957
996 ‎‡2  DBC|87097968420482
996 ‎‡2  DBC|87097968715776
996 ‎‡2  DBC|87097968760437
996 ‎‡2  DNB|124721737
996 ‎‡2  LC|n 2002035331
996 ‎‡2  BIBSYS|90271608
996 ‎‡2  ISNI|0000000024499695
996 ‎‡2  LC|n 2013036480
996 ‎‡2  DBC|870979136854305
996 ‎‡2  BIBSYS|90091394
996 ‎‡2  SELIBR|408595
996 ‎‡2  JPG|500075353
996 ‎‡2  LC|n 2015184221
996 ‎‡2  ISNI|0000000024430743
996 ‎‡2  DBC|870979137756455
996 ‎‡2  PLWABN|9810667477605606
996 ‎‡2  DBC|87097962215518
996 ‎‡2  DNB|1056093455
996 ‎‡2  DNB|1055701680
996 ‎‡2  BIBSYS|90982783
996 ‎‡2  DBC|870979137674793
996 ‎‡2  ISNI|0000000060585013
996 ‎‡2  DBC|87097991690799
996 ‎‡2  DBC|87097947123135
996 ‎‡2  DBC|87097991020726
996 ‎‡2  DBC|87097919179753
996 ‎‡2  W2Z|90293315
996 ‎‡2  ISNI|0000000035994229
996 ‎‡2  ISNI|0000000383691726
996 ‎‡2  BIBSYS|90932622
996 ‎‡2  DBC|870979138358917
996 ‎‡2  BNF|16745998
996 ‎‡2  RERO|A026092966
996 ‎‡2  DBC|87097968529085
996 ‎‡2  DBC|87097961957863
996 ‎‡2  DBC|87097991295180
996 ‎‡2  DBC|87097946471628
996 ‎‡2  BIBSYS|14060256
996 ‎‡2  BIBSYS|90964384
996 ‎‡2  BIBSYS|1523352732218
996 ‎‡2  DNB|105191437X
996 ‎‡2  NKC|xx0130533
996 ‎‡2  DBC|87097919179761
996 ‎‡2  DBC|87097968872014
996 ‎‡2  LC|no2024093081
996 ‎‡2  BIBSYS|90511811
996 ‎‡2  DBC|87097969055281
996 ‎‡2  DNB|171843932
996 ‎‡2  BIBSYS|13009498
996 ‎‡2  ISNI|0000000026523572
996 ‎‡2  BIBSYS|90660546
996 ‎‡2  BIBSYS|1642068439113
996 ‎‡2  BIBSYS|1642068439114
996 ‎‡2  BIBSYS|1642068439115
996 ‎‡2  BIBSYS|1642068439116
996 ‎‡2  BNCHL|10000000000000000175231
996 ‎‡2  DNB|1158007183
996 ‎‡2  W2Z|9008264
996 ‎‡2  DNB|1135672695
996 ‎‡2  DBC|87097968749468
996 ‎‡2  W2Z|3109811
996 ‎‡2  BIBSYS|7053342
996 ‎‡2  W2Z|1523352732218
996 ‎‡2  BIBSYS|12026058
996 ‎‡2  DBC|87097968172365
996 ‎‡2  ISNI|0000000391929167
996 ‎‡2  ISNI|000000002984905X
996 ‎‡2  BNF|12529192
996 ‎‡2  DBC|87097968715741
996 ‎‡2  ISNI|0000000042526191
996 ‎‡2  ISNI|0000000488652416
996 ‎‡2  SUDOC|166618233
996 ‎‡2  DBC|87097991279924
996 ‎‡2  DNB|1155328841
996 ‎‡2  ISNI|0000000065689604
996 ‎‡2  BIBSYS|90211583
996 ‎‡2  W2Z|11046794
996 ‎‡2  ISNI|0000000488608431
996 ‎‡2  NTA|237179202
996 ‎‡2  DBC|87097919452514
996 ‎‡2  BIBSYS|99034136
996 ‎‡2  BIBSYS|1055705
996 ‎‡2  ISNI|0000000021440137
996 ‎‡2  W2Z|90091394
996 ‎‡2  LC|no2022058150
996 ‎‡2  LC|n 2009028058
996 ‎‡2  BIBSYS|6097897
996 ‎‡2  DBC|87097991690764
996 ‎‡2  DBC|87097968977789
996 ‎‡2  BIBSYS|14070371
996 ‎‡2  LC|n 2024063641
996 ‎‡2  DBC|87097968750326
996 ‎‡2  BIBSYS|5029931
996 ‎‡2  NTA|400882035
996 ‎‡2  SUDOC|224431145
996 ‎‡2  RERO|A008836016
996 ‎‡2  DBC|87097969098886
996 ‎‡2  DBC|87097946844645
996 ‎‡2  BIBSYS|14045830
996 ‎‡2  LC|n 97051602
996 ‎‡2  ISNI|0000000025693326
996 ‎‡2  DNB|1157194788
996 ‎‡2  BNF|12152469
996 ‎‡2  DNB|1037624246
996 ‎‡2  DBC|87097968749565
996 ‎‡2  NUKAT|n 2015156229
996 ‎‡2  DBC|87097968469600
996 ‎‡2  DNB|1158265530
996 ‎‡2  DNB|1171352476
996 ‎‡2  DBC|87097947766184
996 ‎‡2  BIBSYS|14029645
996 ‎‡2  DBC|87097968749581
996 ‎‡2  DBC|87097939578689
996 ‎‡2  DBC|87097968749425
996 ‎‡2  W2Z|1642068439113
996 ‎‡2  W2Z|1642068439116
996 ‎‡2  W2Z|1642068439117
996 ‎‡2  DBC|87097968568315
996 ‎‡2  W2Z|1642068439115
996 ‎‡2  DBC|87097991690896
996 ‎‡2  DBC|87097991690950
996 ‎‡2  PLWABN|9810668436105606
996 ‎‡2  UIY|000040849
996 ‎‡2  ISNI|0000000361411121
996 ‎‡2  DBC|87097968129427
996 ‎‡2  SUDOC|177089733
996 ‎‡2  ISNI|0000000485887359
996 ‎‡2  DNB|1062407091
996 ‎‡2  LC|n 2005027479
996 ‎‡2  DBC|87097990498169
996 ‎‡2  DBC|87097968762138
996 ‎‡2  NII|DA06267896
996 ‎‡2  DBC|87097947673259
996 ‎‡2  LC|n 80028369
996 ‎‡2  DBC|87097992288927
996 ‎‡2  LC|n 92072635
996 ‎‡2  DBC|87097991690608
996 ‎‡2  J9U|987007267610905171
996 ‎‡2  CAOONL|ncf11573596
996 ‎‡2  BIBSYS|9008264
996 ‎‡2  DNB|1089096755
996 ‎‡2  DNB|1165103400
996 ‎‡2  DBC|87097968815606
996 ‎‡2  LC|n 82074691
996 ‎‡2  DBC|870979135511773
996 ‎‡2  BIBSYS|90291028
996 ‎‡2  BIBSYS|90259967
996 ‎‡2  DNB|1024975185
996 ‎‡2  DBC|87097968680093
996 ‎‡2  ISNI|0000000037826819
996 ‎‡2  NTA|40234670X
996 ‎‡2  BIBSYS|90298550
996 ‎‡2  DBC|87097968902703
996 ‎‡2  CAOONL|ncf13739220
996 ‎‡2  SUDOC|079405983
996 ‎‡2  BIBSYS|7078326
996 ‎‡2  DBC|87097968045444
996 ‎‡2  NTA|290678528
996 ‎‡2  DBC|87097969375618
996 ‎‡2  DBC|87097968359880
996 ‎‡2  BIBSYS|90943757
996 ‎‡2  W2Z|90773557
996 ‎‡2  CAOONL|ncf11207401
996 ‎‡2  BIBSYS|90263670
996 ‎‡2  LC|nb2021001468
996 ‎‡2  ISNI|0000000025038364
996 ‎‡2  NTA|12826876X
996 ‎‡2  NTA|180480480
996 ‎‡2  DBC|87097968749433
996 ‎‡2  DBC|87097968750318
996 ‎‡2  DNB|1211979997
996 ‎‡2  DBC|87097968871174
996 ‎‡2  CAOONL|ncf10255497
996 ‎‡2  LC|n 2012025527
996 ‎‡2  BIBSYS|3063730
996 ‎‡2  SZ|1223034984
996 ‎‡2  ISNI|0000000107854664
996 ‎‡2  ISNI|0000000429112452
996 ‎‡2  DBC|87097991694174
996 ‎‡2  BIBSYS|3025014
996 ‎‡2  W2Z|9047270
996 ‎‡2  ISNI|0000000384839470
996 ‎‡2  ISNI|0000000075447211
996 ‎‡2  LC|no2009033688
996 ‎‡2  LC|n 81041053
996 ‎‡2  LC|n 85252682
996 ‎‡2  SUDOC|034547142
996 ‎‡2  BIBSYS|90859992
996 ‎‡2  BIBSYS|15016070
996 ‎‡2  ISNI|0000000020360151
996 ‎‡2  ISNI|0000000109054783
996 ‎‡2  JPG|500074780
996 ‎‡2  LC|n 79105174
996 ‎‡2  DBC|87097946291212
996 ‎‡2  DNB|1157182917
996 ‎‡2  LC|no2006104938
996 ‎‡2  ISNI|0000000410202773
996 ‎‡2  BIBSYS|90773557
996 ‎‡2  ISNI|000000038449429X
996 ‎‡2  DBC|87097968749603
996 ‎‡2  DBC|87097946453328
996 ‎‡2  ISNI|0000000449601923
996 ‎‡2  LC|n 80036338
996 ‎‡2  DBC|87097991690918
996 ‎‡2  DBC|87097991687658
996 ‎‡2  BAV|495_164421
996 ‎‡2  DBC|87097919025535
996 ‎‡2  W2Z|14029645
996 ‎‡2  NSK|000164777
996 ‎‡2  NUKAT|n 2019004627
996 ‎‡2  BIBSYS|67318
996 ‎‡2  LC|n 79009185
996 ‎‡2  DBC|87097991763710
996 ‎‡2  NII|DA10198017
996 ‎‡2  RERO|A003640679
996 ‎‡2  RERO|A003640678
996 ‎‡2  BIBSYS|90711223
996 ‎‡2  BIBSYS|4066942
996 ‎‡2  DNB|1324331232
996 ‎‡2  DBC|87097991690772
996 ‎‡2  DBC|87097946896033
996 ‎‡2  DBC|87097969467067
996 ‎‡2  RERO|A027721256
996 ‎‡2  BIBSYS|1492758307957
996 ‎‡2  ISNI|0000000485953774
996 ‎‡2  DNB|1223034984
996 ‎‡2  DBC|87097919213234
996 ‎‡2  BIBSYS|2005849
996 ‎‡2  DBC|87097961814906
996 ‎‡2  NII|DA12425492
996 ‎‡2  LC|no 99004327
996 ‎‡2  LC|n 2012038911
996 ‎‡2  DBC|87097968749557
996 ‎‡2  ISNI|0000000369468894
996 ‎‡2  BIBSYS|1006623
996 ‎‡2  DBC|87097990317261
996 ‎‡2  LC|n 2020040137
996 ‎‡2  DBC|87097991694433
996 ‎‡2  DBC|87097968073723
996 ‎‡2  DBC|87097968750776
996 ‎‡2  DBC|87097991690888
996 ‎‡2  DBC|87097919456730
996 ‎‡2  LC|n 2003055183
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏